Select patients with chondrosarcoma are being enrolled in a random, double-blind Phase 2 clinical trial aiming to investigate a potential treatment for the rare and sometimes fatal cancer.
Arizona Oncology, along with Virginia G. Piper Cancer Center Clinical Trials in Scottsdale, will evaluate the productiveness and safety of IPI-926, an inhibitor of the Hedgehog pathway, vs. placebos in patients who have metastatic or locally advanced, inoperable chondrosarcoma. The inhibitor was discovered by and is seeing development through Infinity Pharmaceuticals Inc.
More than 100 patients are expected to be enrolled into the program. There are no approved chemotherapy treatments available for chondrosarcoma, which effects cartilage.
Those looking for information about the trial's participant-eligibility requirements can contact the cancer care coordinator at 480-323-1339 toll free at 877-273-3713 or by e-mail at firstname.lastname@example.org.